CVI Program Unit(s):
Lipid / Atherosclerosis / CAD / ACS / Prevention
CVI Research Description:
I am interested in the treatment of atherogenic dyslipidemia, and have a particular interest in the mechanism of action and adverse effects of triglyceride-lowering drugs.
Goldberg AC, Dunbar RL, Hemphill L, Babirak SP, Wilson G, Wooten M, Moriarty PM: Retrospective Review of the Effect of Alirocumab on Apheresis. J Clin Lip 11(3), May 2017 Notes: [Accepted for poster presentation to the 2017 National Lipid Association Scientific Sessions]
Ueda M, Burke FM, Walters L, Lalic D, Sikora, Greene H, DerOhannessian S, McIntyre A, deGoma E, Hegele RA, Rader DJ, Dunbar RL: Familial Chylomicron Syndrome: Importance of Discerning the Rare Among the Common. J Clin Lip 11(3), May 2017 Notes: [Accepted for poster presentation to the 2017 National Lipid Association Scientific Sessions]
Dewey FE*, Gusarova V*, Dunbar RL*, O’Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV , Bruse S, Dansky HM , Leader JB, Murray MF, Ritchie MD, Kirchner HL, Habegger L, Lopez A, Penn J, Zhao A, Shao W, Stahl N, Murphy AJ, Hamon S, Bouzelmat A, Zhang R, Shumel B, Pordy R, Gipe D, Herman GA, Sheu WHH , Lee I-T, Liang K-W, Guo X, Rotter JI, Chen Y-D I on behalf of the TAICHI consortium, Kraus WE, Shah SH, Damrauer S, Small A, Rader DJ, Wulff AB, Nordestgaard BG, Tybjærg-Hansen A, van den Hoek AM, Princen HMG, Ledbetter DH, Carey DJ on behalf of the Geisinger-Regeneron DiscovEHR Collaboration, Overton JD, Reid JG, Sasiela WJ, Banerjee P, Shuldiner AR, Borecki IB, Teslovich TM, Yancopoulos GD, Mellis SJ, Gromada J, Baras A : Genetic and Pharmacologic Inactivation of ANGPTL3 and Atherosclerotic Cardiovascular Disease. NEJM April 2017 Notes: [*Co-First Authors, Accepted April 2017]
Millar JS, Lassman ME, Thomas T, Ramakrishnan R, Jumes P, Dunbar RL, deGoma EM, Baer AL, Karmally W, Donovan DS, Rafeek H, Wagner JA, Holleran S, Obunike J, Liu Y, Aoujil S, Standiford T, Gutstein DE, Ginsberg HN, Rader DJ, Reyes-Soffer G: Effects of CETP Inhibition with Anacetrapib on Metabolism of VLDL TG and Plasma Apolipoproteins C-II, C-III, and E. J Lipid Res March 2017 Notes: [Provisionally Accepted]
Cuchel M, Raper AC, Pryma DA, Freifelder RH, Poria R, Cromley D, Li X, Dunbar RL, French B, Qu L, Farver W, Su C-C, Lund-Katz S, Baer A, Ruotolo G, Akerblad P, Ryan CS, Xiao L, Kirchgessner TG, Millar JS, Billheimer JT, Rader DJ : A Novel Approach to Measuring Macrophage-specific Reverse Cholesterol Transport in Vivo in Humans. J Lipid Res February 2017 Notes: Published Online Ahead of Print 2/2017.
Ueda M*, Dunbar RL*, Wolska A, Sikora TU, del Rosario Escobar M, Seliktar N, deGoma E, DerOhannessian S, Morrell L, McIntyre AD, Burke F, Sviridov D, Amar M, Shamburek RD, Freeman L, Hegele RA, Remaley AT, Rader DJ: A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency with Severe Triglyceridemia and Pancreatitis. J Clin Endocrinol Metab 102, February 2017 Notes: [Co-First Author, Accepted for Publication on 1/2017]
Dunbar RL*, Goel H*, Tuteja S, Song W-L,
Nathanson G, Babar Z, Lalic D, Gelfand JM, Rader DJ, Grove GL: Measuring Physical Stigmata of Niacin-Associated Skin Toxicity by Colorimetry, White-Light Spectroscopy, Laser Doppler Flowmetry, and Thermometry in Combination with Symptom Perception Scoring: Methods to Aid Development of Niacin Mimetics. J Lipid Res January 2017 Notes: Co-First Authors, Published Online Ahead of Print 1/2017.
Tuteja S, Wang L, Dunbar RL, Chen J, DerOhannessian S, Marcovina SM, Elam M, MD, Lader E, Rader DJ : Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2 (HCA2), and response to niacin therapy Pharmacogenetics and Genomics 2017 Notes: [Submitted and Reviewed, Readily-Addressed Revisions Requested]
Dunbar RL, Bouzelmat A, Gipe DA, Pordy R, Sasiela W, Mellis S, Banerjee P : Inhibition Of ANGPTL3 By Evinacumab Reduced Triglycerides (TGs) And LDL-C In Subjects Presenting With Modest Elevations In TGs And/or LDL-C, Recapitulating The Hypolipidemic Effects Of Loss-of-function (LoF) Mutations Of ANGPTL3. Circulation Novemeber 2016 Notes: [Oral Presentation to the American Heart Association Scientific Sessions 2016, New Orleans, LA]
Digenio A*, Dunbar RL*, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, Yu R, Singleton W, Baker BF, Bhanot S, Crooke RM: Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes. Diabetes Care 39(8): 1408-1415, August 2016 Notes: [Co-first author]
back to top
Last updated: 04/25/2017
The Trustees of the University of Pennsylvania